Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SV001 in Idiopathic Pulmonary Fibrosis
NCT07121413Phase 2Recruiting
- Sponsor
- Shanghai Synvida Biotechnology Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing SV001 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 1 year. Started Nov 2025; status: recruiting.
02
Drugs
SV001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07121413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121413.